Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Companyâ€™s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-13 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
01/10/26	SEK 29.70	+1.37%	1,841
30/09/26	SEK 29.30	-2.66%	3,800
29/09/26	SEK 30.10	+1.01%	857
28/09/26	SEK 29.80	+0.68%	3,097
25/09/26	SEK 29.60	-2.31%	2,452

Delayed Quote Nasdaq Stockholm

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed Nasdaq Stockholm 15:16:49 01/10/2026 BST			5-day change	1st Jan Change
29.70 ^SEK	+1.37%		-1.98%	+197.00%

09-15	Fluicell: Delayed €0.5m receivable settled	FW
08-28	Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	40.25M 4.03M 3.55M 3.36M 3.04M 5.72M 387M 5.8M 15.49M 198M 15.14M 14.81M 634M	P/E 2024	-1.1x	P/E 2025	-1.65x
Enterprise Value	37.99M 3.81M 3.35M 3.18M 2.87M 5.4M 365M 5.47M 14.62M 187M 14.29M 13.98M 598M	EV / Sales 2024	2.04x	EV / Sales 2025	1.91x
Free-Float	70.1%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	FLUI	Delayed
Deutsche Boerse AG	5J90	Delayed
Boerse Muenchen	5J90	Real-time
Börse Stuttgart	5J90	Delayed

09-15	Fluicell: Delayed €0.5m receivable settled	FW
08-28	Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-28	Fluicell increases revenue and turns to operating profit	FW
05-08	Fluicell reports sharp revenue surge and swings to profit in the first quarter	FW
05-08	Fluicell Q1 net sales up at SEK 6.1 million	RE
05-08	Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Fluicell nominates AstraZeneca executive to Board of Directors	FW
04-30	Committee proposes Niklas Frisk as Fluicell chairman	RE
04-30	Fluicell proposes new Board of Directors	FW
02-20	Fluicell Narrows Operating Loss in Q4, Final Report Confirms	FW
02-20	Fluicell Q4 net sales SEK 3.8 mln	RE
02-20	Fluicell AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-11	Fluicell gets EPO approval for microfluidics patent	RE

Fluicell AB Share Price

Stocks

FLUI

SE0023595459

Biotechnology & Medical Research

Valuation: Fluicell AB

Chart: Fluicell AB

Latest news: Fluicell AB

Press Releases: Fluicell AB

Quotes and Performance

Price Extremes

Managers and Directors: Fluicell AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

02/09/25	Fluicell : and Ambusol enter into exclusive global license and development agreement regarding technology for cancer treatment	PU
22/08/25	Fluicell : receives funding from Breakthrough T1D for collaboration with leading medical university to develop tissue-based type 1 diabetes therapeutics	PU
29/09/21	BioStock: Fluicell partners with big pharma for 3-D bioprinting project	AQ
01/07/21	BioStock: 2021 represents beginning of new era for Fluicell	AQ
18/05/21	BioStock: Fluicell dives into regenerative medicine field	AQ

1 day	+1.37%
1 week	-1.98%
Current month	+1.37%
1 month	-3.26%
3 months	-3.88%
6 months	+123.31%
Current year	+197.00%

1 week	29.2	31.4
1 month	28.4	34.1
Current year	7.65	67.2
1 year	7.65	67.2
3 years	7.45	594.3
5 years	7.45	11,147.5
10 years	7.45	15,330

Manager	Title	Age	Since
Carolina Trkulja CEO	Chief Executive Officer	42	31/12/2022
Gavin Jeffries CTO	Chief Tech/Sci/R&D Officer	46	31/12/2016
Niklas Joakim Wahlberg DFI	Director of Finance/CFO	56	30/06/2023

Director	Title	Age	Since
Daniel T. Chiu BRD	Director/Board Member	54	31/12/2016
Carl Fhager BRD	Director/Board Member	51	31/12/2016
Jan Orwar BRD	Director/Board Member	62	31/12/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FLUICELL AB	+1.37%	-1.98%	+42.79%	-92.49%	4.03M
WUXI APPTEC CO., LTD.	+4.16%	-0.36%	+49.37%	+94.17%	74.46B
ARGENX SE	-0.73%	+0.69%	+27.09%	+80.00%	60.14B
LONZA GROUP AG	-2.28%	-1.23%	+5.31%	+33.89%	48.15B
IQVIA HOLDINGS INC.	-1.58%	-3.28%	+30.53%	+37.20%	44.25B
REVOLUTION MEDICINES, INC.	+2.17%	+4.92%	+357.24%	+701.26%	43.99B
BEONE MEDICINES AG	-0.53%	+1.64%	+9.17%	+104.97%	41.61B
CELLTRION, INC.	-0.67%	+0.17%	+7.60%	+46.37%	29.97B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.16%	+36.77%	+22.78%	29.31B
INSMED INCORPORATED	-2.51%	-7.30%	-23.50%	+344.13%	24.93B
Average	+0.41%	+1.04%	+54.24%	+137.23%	39.68B
Weighted average by Cap.	+0.54%	+1.53%	+59.80%	+153.61%

	2024	2025
Net sales	1.86M 186K 164K 155K 140K 264K 17.86M 268K 715K 9.13M 699K 684K 29.27M	6M 601K 529K 502K 453K 854K 57.65M 865K 2.31M 29.47M 2.26M 2.21M 94.49M
Net income	-15.51M -1.55M -1.37M -1.3M -1.17M -2.21M -149M -2.23M -5.97M -76.16M -5.83M -5.71M -244M	-8.33M -835K -735K -696K -629K -1.18M -80.03M -1.2M -3.21M -40.91M -3.13M -3.07M -131M
Net Debt	-15.92M -1.6M -1.4M -1.33M -1.2M -2.26M -153M -2.29M -6.13M -78.19M -5.99M -5.86M -251M	-2.26M -227K -200K -189K -171K -322K -21.73M -326K -870K -11.11M -851K -832K -35.61M